Gilead Sciences Inc (GILD) 83.37 $GILD
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 117.38 (+0.92), MU: 14.05 (+1.33), PXD: 160.59 (+1.84), GILD: 83.37 (+0.92), EOG: 84.50 (+0.90), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), GOOGL: 714.87 (+4.40), CVX: 104.44 (+2.15), MSFT: 51.91 (+0.92)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.25% Loss
Comtex SmarTrend(R) - Tue Jun 21, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.70 to a high of $83.44. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $82.23 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 83.37 (+0.92)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 83.37 (+0.92), PFE: 34.59 (+0.12), MRK: 57.68 (+0.64), AZN: 29.29 (+0.59)
New Strong Sell Stocks for June 21st
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:53AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ECPG: 24.47 (+0.65), GILD: 83.37 (+0.92), FII: 30.52 (+0.56), FRAN: 10.81 (+0.07), WMS: 27.39 (+0.28)
New Strong Sell Stocks for June 17th
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:19AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AAP: 154.93 (+1.77), GILD: 83.37 (+0.92), ASNA: 7.12 (-0.02), WMS: 27.39 (+0.28), CHCT: 20.52 (+0.03)
Global Chronic Lymphocytic Leukemia Market Growth of 19.16% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AbbVie, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Tue Jun 14, 2:31PM CDT
Research and Markets has announced the addition of the "Global Chronic Lymphocytic Leukemia market 2016-2020" report to their offering.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
BusinessWire - Mon Jun 13, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the 36th Annual William Blair Growth Stock Conference in Chicago.
GILD: 83.37 (+0.92)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.39%
Comtex SmarTrend(R) - Fri Jun 10, 12:09PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.35 to a high of $85.17. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $85.65 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
BusinessWire - Thu Jun 09, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2016 Healthcare Conference in New York on Friday, June 10 at 10:30 a.m. Eastern Time.
GILD: 83.37 (+0.92)
Gilead Sciences (GILD) Breaks Through Support at $86.80
Comtex SmarTrend(R) - Thu Jun 09, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $87.44 today and has reached the first level of support at $86.80. Analysts will be watching for a cross of the next downside pivot targets of $86.17 and $84.90.
GILD: 83.37 (+0.92)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.95 (+0.26), LMT: 240.00 (+1.83), GE: 31.19 (+0.41), F: 13.40 (+0.22), RF: 9.45 (+0.33), NKE: 54.12 (-0.45), WMT: 72.10 (+0.35), SRE: 111.08 (+1.55), PEP: 104.44 (+0.70), JLL: 117.49 (+4.75), AAWW: 43.09 (+1.03), AGR: 43.81 (+0.50), ANF: 19.33 (+0.33), BANC: 19.60 (+0.35), AJG: 47.56 (+0.76), MA: 95.71 (+1.65), CMS: 43.59 (-0.06), FEYE: 16.88 (+0.59), INGR: 125.97 (+1.42), ETH: 33.00 (+0.10), ICE: 256.05 (+4.05), AHS: 40.31 (+0.83), EGBN: 50.45 (+2.77), INOV: 17.74 (+0.09), WFC: 47.91 (+0.94), GSK: 42.56 (+0.80), HPQ: 12.95 (+0.34), ORCL: 40.83 (+0.82), DRI: 67.98 (+0.80), MSEX: 39.50 (+0.13), GILD: 83.37 (+0.92), CVS: 94.02 (+0.29), TAHO: 13.27 (+0.13), OSK: 48.64 (+0.91)
Should You Buy Gilead Sciences Inc?
Dana Blankenhorn - Amigobulls - Thu Jun 09, 2:49AM CDT
The P/E multiple is below 8 as analysts see falling sales. Do not expect a hasty or conventional move from Gilead Sciences Inc (NASDAQ:GILD).
GILD: 83.37 (+0.92)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 10.15 (+0.26), GS: 152.66 (+4.52), GILD: 83.37 (+0.92), MRK: 57.68 (+0.64), CMG: 408.89 (+15.90), GPS: 20.93 (+0.32), AAPL: 96.10 (+0.55)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.75 (+0.39), GILD: 83.37 (+0.92), COST: 157.03 (-1.09), ULTA: 242.08 (+3.85), WDC: 50.81 (+2.46)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 95.20 (+1.39), VRX: 22.25 (+0.61), GILD: 83.37 (+0.92)
Global Sickle Cell Disease Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Wed Jun 08, 6:15AM CDT
Research and Markets has announced the addition of the "Sickle Cell Disease Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
BusinessWire - Tue Jun 07, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Ranchos Palos Verdes, CA on Wednesday, June 8 at 11:20 a.m. Pacific Time.
GILD: 83.37 (+0.92)
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 117.38 (+0.92), MU: 14.05 (+1.33), PXD: 160.59 (+1.84), GILD: 83.37 (+0.92), EOG: 84.50 (+0.90), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), GOOGL: 714.87 (+4.40), CVX: 104.44 (+2.15), MSFT: 51.91 (+0.92)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.25% Loss
Comtex SmarTrend(R) - Tue Jun 21, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.70 to a high of $83.44. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $82.23 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 83.37 (+0.92)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 83.37 (+0.92), PFE: 34.59 (+0.12), MRK: 57.68 (+0.64), AZN: 29.29 (+0.59)
New Strong Sell Stocks for June 21st
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:53AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ECPG: 24.47 (+0.65), GILD: 83.37 (+0.92), FII: 30.52 (+0.56), FRAN: 10.81 (+0.07), WMS: 27.39 (+0.28)
New Strong Sell Stocks for June 17th
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:19AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AAP: 154.93 (+1.77), GILD: 83.37 (+0.92), ASNA: 7.12 (-0.02), WMS: 27.39 (+0.28), CHCT: 20.52 (+0.03)
Global Chronic Lymphocytic Leukemia Market Growth of 19.16% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AbbVie, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Tue Jun 14, 2:31PM CDT
Research and Markets has announced the addition of the "Global Chronic Lymphocytic Leukemia market 2016-2020" report to their offering.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
BusinessWire - Mon Jun 13, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the 36th Annual William Blair Growth Stock Conference in Chicago.
GILD: 83.37 (+0.92)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.39%
Comtex SmarTrend(R) - Fri Jun 10, 12:09PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.35 to a high of $85.17. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $85.65 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
BusinessWire - Thu Jun 09, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2016 Healthcare Conference in New York on Friday, June 10 at 10:30 a.m. Eastern Time.
GILD: 83.37 (+0.92)
Gilead Sciences (GILD) Breaks Through Support at $86.80
Comtex SmarTrend(R) - Thu Jun 09, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $87.44 today and has reached the first level of support at $86.80. Analysts will be watching for a cross of the next downside pivot targets of $86.17 and $84.90.
GILD: 83.37 (+0.92)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.95 (+0.26), LMT: 240.00 (+1.83), GE: 31.19 (+0.41), F: 13.40 (+0.22), RF: 9.45 (+0.33), NKE: 54.12 (-0.45), WMT: 72.10 (+0.35), SRE: 111.08 (+1.55), PEP: 104.44 (+0.70), JLL: 117.49 (+4.75), AAWW: 43.09 (+1.03), AGR: 43.81 (+0.50), ANF: 19.33 (+0.33), BANC: 19.60 (+0.35), AJG: 47.56 (+0.76), MA: 95.71 (+1.65), CMS: 43.59 (-0.06), FEYE: 16.88 (+0.59), INGR: 125.97 (+1.42), ETH: 33.00 (+0.10), ICE: 256.05 (+4.05), AHS: 40.31 (+0.83), EGBN: 50.45 (+2.77), INOV: 17.74 (+0.09), WFC: 47.91 (+0.94), GSK: 42.56 (+0.80), HPQ: 12.95 (+0.34), ORCL: 40.83 (+0.82), DRI: 67.98 (+0.80), MSEX: 39.50 (+0.13), GILD: 83.37 (+0.92), CVS: 94.02 (+0.29), TAHO: 13.27 (+0.13), OSK: 48.64 (+0.91)
Should You Buy Gilead Sciences Inc?
Dana Blankenhorn - Amigobulls - Thu Jun 09, 2:49AM CDT
The P/E multiple is below 8 as analysts see falling sales. Do not expect a hasty or conventional move from Gilead Sciences Inc (NASDAQ:GILD).
GILD: 83.37 (+0.92)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 10.15 (+0.26), GS: 152.66 (+4.52), GILD: 83.37 (+0.92), MRK: 57.68 (+0.64), CMG: 408.89 (+15.90), GPS: 20.93 (+0.32), AAPL: 96.10 (+0.55)
Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.75 (+0.39), GILD: 83.37 (+0.92), COST: 157.03 (-1.09), ULTA: 242.08 (+3.85), WDC: 50.81 (+2.46)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 95.20 (+1.39), VRX: 22.25 (+0.61), GILD: 83.37 (+0.92)
Global Sickle Cell Disease Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Novartis, Gilead Sciences - Research and Markets
BusinessWire - Wed Jun 08, 6:15AM CDT
Research and Markets has announced the addition of the "Sickle Cell Disease Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
GILD: 83.37 (+0.92)
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
BusinessWire - Tue Jun 07, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Ranchos Palos Verdes, CA on Wednesday, June 8 at 11:20 a.m. Pacific Time.
GILD: 83.37 (+0.92)
